Drugs / STSG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03394612 | Feb 2018 → Dec 2023 overdue | — | CUTISS AG | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | CUTISS AG | Results New publication reports 1-year phase II results for denovoSkin™ in reconstructive surgery cutiss.swiss ↗
According to the publication, denovoSkin™ demonstrated significantly better scar quality than STSG at 3 months, with benefits maintained at 12 months. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | CUTISS AG | New publication reports 1-year phase II results for denovoSkin™ in reconstructive surgery cutiss.swiss ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STSG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03394612 ↗ |